Improve motor symptoms via glucose
- Trial ID
- NCT05998772
- Official Title
- Influence of Glucose on Metabolism and Clinical Symptoms of Patients With Parkinson's Disease
- Goal
- Improve motor symptoms via glucose
- Status
- RECRUITING
- Sponsor
- University Hospital Schleswig-Holstein
- Study Type
- OBSERVATIONAL
- Enrollment
- 50 participants
- Conditions
- Parkinson Disease, Nutritional and Metabolic Diseases, Sugar Intake
- Interventions
- Oral Glucose Tolerance Test, Placebo Oral Glucose Tolerance Test
Plain-Language Summary
The goal is to see how a glucose challenge changes metabolism and short-term Parkinson's symptoms, and whether people who crave sweets react differently. Participants get an oral glucose tolerance test and a placebo version, so researchers can compare blood glucose and metabolic markers along with motor and nonmotor symptom changes after a sugary drink versus a non‑sugar control; participants pause their morning Parkinson meds to avoid confounding. The trial is looking for people aged 50 to 80 with Parkinson's at Hoehn and Yahr stage 1.5 to 3 who can give consent and can safely skip their morning antiparkinsonian meds. People with diabetes or prediabetes, pacemakers, or on medications that affect glucose metabolism are excluded.
Locations
- Department for Neurology, University of Kiel, Kiel, Germany
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Oral Glucose Tolerance Test. The goal is to see how a glucose challenge changes metabolism and short-term Parkinson's symptoms, and whether people who crave sweets react differently. Participants get an oral glucose tolerance test and a placebo version, so researchers can compare blood glucose and metabolic markers along with motor and nonmotor symptom changes after a sugary drink versus a non‑sugar control; participants pause their morning Parkinson meds to avoid confounding. The trial is looking for people aged 50 to 80 with Parkinson's at Hoehn and Yahr stage 1.5 to 3 who can give consent and can safely skip their morning antiparkinsonian meds. People with diabetes or prediabetes, pacemakers, or on medications that affect glucose metabolism are excluded.
- Who can participate?
- Participants must be between 50 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 3 months.